Clinical Trials Browser

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors

NCT06806930 2026-03-03

Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)

Phase 2 Recruiting

90 enrolled

Breast

Breast Neoplasms, Carcinoma, Neoplasms

NCT07072728 2026-03-03

Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder

Phase 2 Recruiting

87 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologic

Adjustment Disorders, Breast Neoplasms, Kidney Neoplasms, Melanoma, Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT07446452 2026-03-03

Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

Phase 2 Recruiting

37 enrolled

Breast

HER2-low Breast Cancer

NCT07447050 2026-03-03

Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial

Phase 2 Recruiting

24 enrolled

BreastGastrointestinalGynecologicHead & NeckSarcomaThoracic

Breast Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms

NCT05325632 2026-03-02

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

Phase 2 Recruiting

53 enrolled

Breast

Breast Neoplasms

NCT06434064 2026-03-02

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Phase 2 Recruiting

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06486883 2026-03-02

PONTIAC

Phase 2 Recruiting

200 enrolled

Breast

Advanced Breast Cancer

NCT07342283 2026-03-02

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer

Phase 2 Recruiting

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03808337 2026-02-27

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

Phase 2 Recruiting

145 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT04468061 2026-02-27

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Phase 2 Recruiting

110 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05467891 2026-02-27

RaPhLRR

Phase 2 Recruiting

200 enrolled

Breast

Locoregional Recurrence

NCT06179303 2026-02-27

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Phase 2 Recruiting

60 enrolled

Breast

Anatomic Stage III Breast Cancer AJCC v8

NCT06750484 2026-02-27

Trial of Trastuzumab Deruxtecan in Previously Treated HER2

Phase 2 Recruiting

40 enrolled

Breast

Breast Cancer Metastatic

NCT07053085 2026-02-27

A Study of Surgery and Radiotherapy in People With Breast Cancer

Phase 2 Recruiting

162 enrolled

Breast

Breast Neoplasms

NCT06099769 2026-02-25

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

Phase 2 Recruiting

201 enrolled

Breast

Breast Neoplasms

NCT06695845 2026-02-25

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Phase 2 Recruiting

200 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06802757 2026-02-25

PRISM-TNBC

Phase 2 Recruiting

72 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06016387 2026-02-23

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

Phase 2 Recruiting

30 enrolled

Breast

Breast Neoplasms, Meningeal Neoplasms